Down-regulation of A-FABP predicts nonmuscle invasive bladder cancer progression: Investigation with a long term clinical follow-up

Non-muscle invasive bladder cancers (NMIBC: pTa, pT1) are characterised by a high risk of recurrence and/or progression. Identification of prognostic markers is needed to improve both diagnosis and management of the disease.